<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079127</url>
  </required_header>
  <id_info>
    <org_study_id>09H08</org_study_id>
    <nct_id>NCT04079127</nct_id>
  </id_info>
  <brief_title>Avenir Müller Hip Stem Post Market Surveillance Study</brief_title>
  <official_title>A Multi-centre, Non-comparative, Retrospective Post-market Surveillance Study to Obtain Clinical Outcomes Data on the Zimmer Avenir Müller Hip Stem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Post Market Clinical Follow up study to fulfil the post market surveillance
      obligations according to Medical Device Directive and European Medical Device Vigilance
      System (MEDDEV) 2.12-2. The data collected from this study will serve the purpose of
      confirming safety and performance of the Avenir Müller Hip Stem.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this post market surveillance study is to obtain outcome data on the Avenir
      Müller Hip Stem by analysis of standard scoring systems, radiographs and adverse event
      records, and thus to assess the long-term performance and safety of this implant.

      This is a multi-centre, retrospective post-market surveillance study involving orthopaedic
      surgeons skilled in hip surgery. Each case enrolled has received the Avenir Müller Hip Stem
      for a primary hip arthroplasty. The Avenir Müller Hip Stem is CE marked (European Conformity)
      and commercially available.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2010</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 29, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Pain and Functional Performance Determined by the Harris Hip Score</measure>
    <time_frame>10 years</time_frame>
    <description>The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication.
The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed when walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction.
There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmation of Safety Based on Complications</measure>
    <time_frame>10 years</time_frame>
    <description>Number of patients with adverse events related to the implant will be reported. Adverse events include: dislocations of the hip, revisions and removals of the implants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survivorship of the Implant Using Kaplan Meier Analysis</measure>
    <time_frame>10 years</time_frame>
    <description>Number of implant revisions will be counted.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Fracture of Hip</condition>
  <condition>Dislocated Hip</condition>
  <condition>Osteonecrosis</condition>
  <condition>Post-traumatic; Arthrosis</condition>
  <condition>Subluxation Hip</condition>
  <arm_group>
    <arm_group_label>Patients suffering from severe hip pain and disability</arm_group_label>
    <description>Patients in need of a total hip arthroplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.</intervention_name>
    <description>Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.</description>
    <arm_group_label>Patients suffering from severe hip pain and disability</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from severe hip pain and disability requiring a total hip arthroplasty.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients able to participate in a follow-up program based upon physical examination
             and medical history.

          -  Patients or patient's legal representatives who have given written consent to take
             part in the study by signing the 'Patient Consent Form'.

          -  18 years minimum.

          -  Male and female.

          -  Baseline data exist (pre-, peri- and immediate postoperative)

        Exclusion Criteria:

          -  Patients who are unwilling or unable to comply with the follow-up program.

          -  Known pregnancy.

          -  Patients who are skeletally immature.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Vivoda</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <link>
    <url>https://journals.sagepub.com/eprint/Tii3vM7BGcZpCAEFHQ2f/full</url>
    <description>Hip International</description>
  </link>
  <results_reference>
    <citation>Erivan R, Villatte G, Brientini JM, Kreider D, Descamps S, Boisgard S. 7-year results of primary total hip arthroplasty with the uncemented Avenir stem. Hip Int. 2019 Jul;29(4):418-423. doi: 10.1177/1120700018810211. Epub 2018 Nov 11.</citation>
    <PMID>30415580</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <results_first_submitted>April 15, 2020</results_first_submitted>
  <results_first_submitted_qc>June 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2020</results_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 6, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT04079127/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Suffering From Severe Hip Pain and Disability</title>
          <description>Patients in need of a total hip arthroplasty.
Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.: Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89">89 cases have completed the study, and all 10 year data of 81 were available for analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Suffering From Severe Hip Pain and Disability</title>
          <description>Patients in need of a total hip arthroplasty.
Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem and who met the study inclusion/exclusion criteria .</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) kg/m2</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.1" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Pain and Functional Performance Determined by the Harris Hip Score</title>
        <description>The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication.
The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed when walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction.
There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).</description>
        <time_frame>10 years</time_frame>
        <population>The HHS values are within the interval 0-100 points and the higher the score is, the better the outcome is for the individuals. The results are interpreted with the following ratings: &lt;70 points = poor result; 70–79 points = fair, 80–89 points = good, and 90–100 points = excellent.
Number Of Unilateral Patients: 68; Number Of Bilateral Patients:7</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Suffering From Severe Hip Pain and Disability</title>
            <description>Patients in need of a total hip arthroplasty.
Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.: Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pain and Functional Performance Determined by the Harris Hip Score</title>
          <description>The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication.
The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed when walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction.
There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).</description>
          <population>The HHS values are within the interval 0-100 points and the higher the score is, the better the outcome is for the individuals. The results are interpreted with the following ratings: &lt;70 points = poor result; 70–79 points = fair, 80–89 points = good, and 90–100 points = excellent.
Number Of Unilateral Patients: 68; Number Of Bilateral Patients:7</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmation of Safety Based on Complications</title>
        <description>Number of patients with adverse events related to the implant will be reported. Adverse events include: dislocations of the hip, revisions and removals of the implants.</description>
        <time_frame>10 years</time_frame>
        <population>Revisions due to any component (Avenir Muller Hip Stem, Acetabular Insert , Acetabular Cup...) complication.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Suffering From Severe Hip Pain and Disability</title>
            <description>Patients in need of a total hip arthroplasty.
Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.: Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmation of Safety Based on Complications</title>
          <description>Number of patients with adverse events related to the implant will be reported. Adverse events include: dislocations of the hip, revisions and removals of the implants.</description>
          <population>Revisions due to any component (Avenir Muller Hip Stem, Acetabular Insert , Acetabular Cup...) complication.</population>
          <units>Cases</units>
          <param>Number</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survivorship of the Implant Using Kaplan Meier Analysis</title>
        <description>Number of implant revisions will be counted.</description>
        <time_frame>10 years</time_frame>
        <population>The Kaplan-Meier survival rate at 10 years post-surgery, with Avenir Muller Hip Stem revision for any reason as endpoint .
Number of Unilateral Patients: 84; Number of Bilateral Patients: 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Suffering From Severe Hip Pain and Disability</title>
            <description>Patients in need of a total hip arthroplasty.
Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.: Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.</description>
          </group>
        </group_list>
        <measure>
          <title>Survivorship of the Implant Using Kaplan Meier Analysis</title>
          <description>Number of implant revisions will be counted.</description>
          <population>The Kaplan-Meier survival rate at 10 years post-surgery, with Avenir Muller Hip Stem revision for any reason as endpoint .
Number of Unilateral Patients: 84; Number of Bilateral Patients: 4.</population>
          <units>percentage implant survival</units>
          <param>Number</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected preoperatively, intraoperatively and postoperatively (at 3-4 years, 5 years, 7 years and 10 years postoperative).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients Suffering From Severe Hip Pain and Disability</title>
          <description>Patients in need of a total hip arthroplasty.
Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.: Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Scar Inflammation</sub_title>
                <description>Treated by Amoxiciline</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <description>Treated by a pacemaker</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Cause of Death unknown.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Reaction Due To Metal Bearing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Deep Infection (&gt;6 Weeks</sub_title>
                <description>Treated by the revision of the whole prosthesis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Deep Infection (&gt;6 Weeks)</sub_title>
                <description>Treated by rifadin and batrim</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Metallosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <description>Treated with a catheter</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Post traumatic Pain on acetabular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cup pain after Trauma</sub_title>
                <description>Treated by revision of the Cup Head</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fracture of Femoral Shaft</sub_title>
                <description>Treated by revision of the Avenir Muller Stem</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bascule Implant cotyl</sub_title>
                <description>Treated by revision</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Bascule Insert acetabular</sub_title>
                <description>Treated by revision of the cup head</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Calcar crack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Treated by Medication</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Treated by Catheter</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Treated by operation</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <description>Treated by hospitalizations and chemotherapy</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <description>Treated by Electrical Radioscopic Treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <description>Treated by medical corticosteroid.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instability</sub_title>
                <description>Kept under surveillance</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Treated by Antibiotics.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Respiratory Infection</sub_title>
                <description>Treated by Antibiotics</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing Spondylartis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone</sub_title>
                <description>Treated by Lithotripsy</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Nephrectomy L and Partiel R</sub_title>
                <description>Treated by surgery and hospitalization.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dislocation</sub_title>
                <description>Treated by reduction with general anaesthesia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Subluxation</sub_title>
                <description>Treated by hospitalisation traction Nonsteroidal anti-inflammatory drugs (NSAIDs)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dislocation</sub_title>
                <description>Treated by reduction traction</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emilie Rohmer, Clinical Operations Manager</name_or_title>
      <organization>Zimmer Biomet</organization>
      <phone>+41 58 85 48210</phone>
      <email>Emilie.Rohmer@zimmerbiomet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

